Alpha Therapy’s Radiopharma Unicorn Surge -( $AZN $BMY $NVS $IBB $XBI ) by John F. Heerdink, Jr. 2 days ago Read more GeoVax Joins the “Post‑Prasad” Party With a Well‑Timed Signal to Buyers and Bureaucrats -( $GOVX $INO $TNXP $VRTX $IBB $XBI ) by John F. Heerdink, Jr. 4 days ago Read more Wegovy Goes Online, Insulin Goes Tubeless: Why Metabolic Care Suddenly Looks Sexy -( $HIMS $MODD $NVO ) by John F. Heerdink, Jr. March 9, 2026 Read more The Billion-Dollar Hangover of Falling Vaccination Rates And Why GeoVax Brought the Coffee -( $GOVX $IBB $XBI ) by John F. Heerdink, Jr. March 9, 2026 Read more From Under the Radar to Over the Moon? Raymond James Puts a Strong‑Buy Spotlight on Eupraxia – $EPRX $IBB $SNY $XBI ) by John F. Heerdink, Jr. March 9, 2026 Read more Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB ) by John F. Heerdink, Jr. March 6, 2026 Read more FDA’s New Bonus Plan: Can Cash Tips Speed Up Drug Reviews Without Cutting Corners? -( $IBB $XBI ) by John F. Heerdink, Jr. March 5, 2026 Read more Insulin Pumps Have a Moment: Why Insulet Is Growing Like a Tech Stock, Not a Medical Device -( $PODD $TNDM $MODD ) by John F. Heerdink, Jr. March 4, 2026 Read more Genevant, Arbutus and Moderna: How a Once-in-a-Lifetime Pandemic Ended With a Once-in-a-Lifetime Check -( $MRNA $ABUS ) by John F. Heerdink, Jr. March 4, 2026 Read more Modular Medical’s $12 Million Shot in the Arm: Can a Tiny Pump Make a Big Splash in Diabetes Care? -( $MODD $MDT $PODD $TNDM ) by John F. Heerdink, Jr. March 3, 2026 Read more Read more
